KR20230112622A - 알파-7 니코틴성 아세틸콜린 수용체 작용제를 사용한 대중 발표 불안증의 치료 - Google Patents

알파-7 니코틴성 아세틸콜린 수용체 작용제를 사용한 대중 발표 불안증의 치료 Download PDF

Info

Publication number
KR20230112622A
KR20230112622A KR1020237016855A KR20237016855A KR20230112622A KR 20230112622 A KR20230112622 A KR 20230112622A KR 1020237016855 A KR1020237016855 A KR 1020237016855A KR 20237016855 A KR20237016855 A KR 20237016855A KR 20230112622 A KR20230112622 A KR 20230112622A
Authority
KR
South Korea
Prior art keywords
sad
individual
compound
anxiety
symptom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237016855A
Other languages
English (en)
Korean (ko)
Inventor
미하엘 폴리머로풀로스
윤성 허
크리스토스 폴리머로풀로스
Original Assignee
반다 파마슈티칼즈, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 반다 파마슈티칼즈, 인코퍼레이티드. filed Critical 반다 파마슈티칼즈, 인코퍼레이티드.
Publication of KR20230112622A publication Critical patent/KR20230112622A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
KR1020237016855A 2020-11-25 2021-11-24 알파-7 니코틴성 아세틸콜린 수용체 작용제를 사용한 대중 발표 불안증의 치료 Pending KR20230112622A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063118121P 2020-11-25 2020-11-25
US202063118132P 2020-11-25 2020-11-25
US63/118,132 2020-11-25
US63/118,121 2020-11-25
US202163158449P 2021-03-09 2021-03-09
US63/158,449 2021-03-09
PCT/US2021/060720 WO2022115526A1 (en) 2020-11-25 2021-11-24 Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist

Publications (1)

Publication Number Publication Date
KR20230112622A true KR20230112622A (ko) 2023-07-27

Family

ID=78957498

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237016855A Pending KR20230112622A (ko) 2020-11-25 2021-11-24 알파-7 니코틴성 아세틸콜린 수용체 작용제를 사용한 대중 발표 불안증의 치료

Country Status (8)

Country Link
US (1) US20230381169A1 (https=)
EP (1) EP4251158A1 (https=)
JP (1) JP2023553354A (https=)
KR (1) KR20230112622A (https=)
AU (1) AU2021387993A1 (https=)
CA (1) CA3199760A1 (https=)
MX (1) MX2023005895A (https=)
WO (1) WO2022115526A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
JP6263469B2 (ja) 2011-07-15 2018-01-17 ノバルティス アーゲー アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法
EP2742940B1 (en) * 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily

Also Published As

Publication number Publication date
AU2021387993A9 (en) 2024-02-08
CA3199760A1 (en) 2022-06-02
JP2023553354A (ja) 2023-12-21
AU2021387993A1 (en) 2023-06-08
US20230381169A1 (en) 2023-11-30
EP4251158A1 (en) 2023-10-04
WO2022115526A1 (en) 2022-06-02
MX2023005895A (es) 2023-06-06

Similar Documents

Publication Publication Date Title
Rosenzweig et al. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers
JP2025510294A (ja) 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2022514194A (ja) 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
WO2023186823A1 (en) Treatment of cognitive dysfunction
US11826321B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
AU2022234744B2 (en) Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
KR20210114946A (ko) 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진
TW202038955A (zh) 用於治療多巴胺性cns病症之ly3154207劑量療法
JP7766026B2 (ja) 自閉症スペクトラム障害の症状を治療する方法
KR20230112622A (ko) 알파-7 니코틴성 아세틸콜린 수용체 작용제를 사용한 대중 발표 불안증의 치료
RU2840314C1 (ru) Лечение боязни публичного выступления агонистом альфа-7 никотинового ацетилхолинового рецептора
US20240197698A1 (en) Treatment of acute anxiety with an alpha-7 nicotinic acetylcholine receptor modulator
CN116761604A (zh) 用α-7烟碱型乙酰胆碱受体激动剂治疗当众讲话焦虑
RU2844953C1 (ru) Способы лечения симптомов расстройства аутистического спектра
TW202606707A (zh) 不具副作用之９－［４－（環己氧基）苯基］－７－甲基－３，４－二氫吡并［２，１－ｃ］［１，２，４］噻二－２，２－二氧化物投與方法
TW202608450A (zh) 憂鬱症及認知障礙之治療
Duncan et al. Antidepressants
Tecco et al. Citalopram may reduce sympathoadrenal hyperactivity in elderly depressed patients: an open multicenter study in Belgium and Luxembourg
HK40112834A (zh) 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
HK40105808A (zh) 美维达林和其他d1正向别构调节剂在幻觉和痴呆相关精神病的治疗中的用途
HK40068315A (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
EA044015B1 (ru) Дейтетрабеназин для лечения дискинезии при церебральном параличе
Kumar S. 28.04 Muscarinic agonists in the treatment of alzheimer's disease
Hegeman et al. CNS effects of indomethacin, should patients really be cautioned about decreased mental alertness and motor coordination?
WO2012048871A1 (en) Memantine for improving cognitive performance in subjects

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230518

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241122

Comment text: Request for Examination of Application